Further trial disruptions due to the Russian invasion of Ukraine
A further three trials have been disrupted by the Russia-Ukraine conflict since 28 April, bringing the total number to 11.
By
A further three trials have been disrupted by the Russia-Ukraine conflict since 28 April, bringing the total number to 11.
ByEight trials have so far been disrupted due to the Russian invasion of Ukraine, and another eight may be impacted…
ByCertain big pharma companies have reconsidered their clinical trial footprint in Russia in response to the Ukraine invasion. Clinical Trials…
ByIn an analysis by Clinical Trials Arena, Pfizer ranks ninth in the top 10 pharma companies with an ongoing and…
Top-line data from the VALOR-CKD trial of veverimer is now expected in the fourth quarter of this year.
Even if enrollment hiatus is lifted, logistical issues such as sending samples to and from Russia another setback.
ByThere are at least five pharma companies and two research centres headquartered in Russia with a clinical trial site recruiting…
ByThe Phase III EMERGENT-3 trial is assessing the safety and efficacy of KarXT for schizophrenia in the US and Ukraine.
Thank you for subscribing to Clinical Trials Arena